Genemed Biotechnologies is categorized under in South San Francisco, CA and active since 1987.
Genemed Biotechnologies was established in 1987, and today employs 1 to 4, earning $5.000.000 to $9.999.999 per year. This is a business, which does work in the B2B market, and is classified as a , under code number 3399990 by the NAICS.
If you are seeking more information, feel free to contact Paul Kao, Chief Executive Officer at the company’s single location by writing to 458 Carlton Court, South San Francisco, California CA 94080 or by phoning (650) 952-0110. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Genemed Biotechnologies |
| Contact Person: | Paul Kao, Chief Executive Officer |
| Address: | 458 Carlton Court, South San Francisco, California 94080 |
| Phone Number: | (650) 952-0110 |
| Website Address: | genemed.com |
| Annual Revenue (USD): | $5.000.000 to $9.999.999 |
| Founded: | 1987 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2B (Business to Business) |
| Business Category: | |
| SIC Code: | 3841 |
| NAICS Code: | 3399990 |
| Share This Business: |
Genemed Biotechnologies was started in 1987 to provide professional under the SIC code 3841 and NAICS code 3399990. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $5.000.000 to $9.999.999 per annum.
Feel free to contact Paul Kao, Chief Executive Officer for inquiries that concern Genemed Biotechnologies by calling the company number (650) 952-0110, as your correspondence is most welcome. Additionally, the physical location of the single location of Genemed Biotechnologies can be found at the coordinates 37.65701,-122.3929 as well as the street address 458 Carlton Court in South San Francisco, California 94080.
For its online presence, you may visit Genemed Biotechnologies’s website at genemed.com and engage with its social media outlets through on Twitter and on Facebook.